The Legal Cannabis Industry is Growing Around the World

Thursday, March 30, 2017 Drug News
Email Print This Page Comment
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, March 30, 2017 /PRNewswire/ --

A report published by Grand

View Research, Inc. projects that the global medical cannabis market will reach a value of USD 55.8 billion by 2025. The growing number of states and countries getting approval for using it in therapeutic applications is
one of the crucial factors driving the demand over the coming few years. The increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of cannabis is among the significant factors which are expected to push the market to new highs over the coming years. ChineseInvestors.com Inc. (OTC: CIIX), Mentor Capital, Inc. (OTC: MNTR), Lexaria Bioscience Corp. (OTC: LXRP), Kush Bottles Inc. (OTC: KSHB), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)

The Arcview Group pointed out that in the relatively mature Colorado market, there are now hundreds of branded products on shelves. The top five brands accounted for nearly half of all edible sales. "The explosion in the number of brands and products is dizzying," said Arcview Editor-in-Chief Tom Adams. "When the #1 concentrate brand in CO grows 84 percent but its market share percentage remains constant it becomes clear we are in a remarkable business boom. It reminds me of 1998, when Google was just one of dozens of search engines, or 1988 when Blockbuster was just one of dozens of video store chains; future market leaders are just now being launched."

ChineseInvestors.com Inc. (OTCQB: CIIX) is a premier financial information website for Chinese-speaking investors. Earlier today the company announced that, "its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company. Building on the success that CIIX enjoyed through its investment in early-stage firm Medicine Man Technologies, the Company is pleased to announce another strategic investment in the cannabis industry.  

Breakwater MB was formed by CIIX board member and former CFO Paul Dickman as a means to invest capital in and provide consulting services to private, cannabis-focused companies as they transition into the public market. The invested capital will primarily be used to cover the costs of becoming a publicly traded company, a strategy CIIX expects will provide significant investment appreciation and opportunity for liquidity. All opportunities will be evaluated by the investment committee comprised of CIIX CEO Warren Wang, Medicine Man Technologies (OTCQB: MDCL) CEO Andy Williams, and Paul Dickman, the CFO of Medicine Man and managing member of Breakwater MB.  

 "With the gradual opening up of the cannabis industry in the U.S., the potential development of cannabis companies will be huge in the future. U.S. states will continue to issue cannabis licenses to applicants, while licensed cannabis stores will continue to have long queues of consumers. As a result, I believe that CIIX will recognize generous returns from this investment in a cannabis-focused investment and consulting company," says Wang.

In addition, Mr. Wang stated, "Breakwater MB is managed by Mr. Dickman, who has extensive experience in the financial and capital markets. He served as the CFO of CIIX from July 2010 - October 2016 and has served as the CFO for companies in a variety of industries both domestically and abroad.  As a licensed CPA since 2005, Mr. Dickman has successfully taken numerous companies through multiple fund raising transactions, including private placements of debt and equity and IPOs. Based on his rich experience in the financial market and unique investment vision, I am confident in this mutually beneficial cooperation."

Mentor Capital, Inc. (OTCQB: MNTR) makes medical marijuana and cannabis related acquisitions and funding to established founders as a publicly traded operating company with a $23 million capital structure. The company recently announced that it has closed and paid in cash and stock a $1.0 million multi-faceted financing program for G FarmaLabs Limited. The initial Mentor financing is structured to provide funding for real estate and working capital. G Farma has also been provided Mentor public shares to participate in any potential upside that may or may not occur on account of the G Farma relationship with Mentor.  

Lexaria Bioscience Corp. (OTCQB: LXRP) is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. On March 22nd the company announced the introduction of the TurboCBD™ brand of technologically enhanced, high absorption full spectrum hemp oil capsules. Lexaria's TurboCBD™ capsules are specially formulated with the finest American Ginseng and Ginkgo Biloba for support of enhanced focus and memory, and reduced stress and fatigue.

Kush Bottles Inc. (OTCQB: KSHB) provides packaging products and solutions to producers, processors and retailers operating in the regulated medical and recreational cannabis industry. The company recently revealed that it has added two new distribution partners in Hawaii and Puerto Rico, two key medical cannabis markets. The move will significantly enhance the company's ability to attract and service new customers in these emerging markets. The company's Hawaii distribution partner will service the island's dispensaries that provide products to registered patients. Hawaii's reciprocity program will also allow sales to patients with valid medical marijuana cards who are visiting from other states. According to the Hawaii Department of Business, Economic Development and Tourism, Hawaii had approximately 9 million tourists visit in 2016.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, JBT-101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In December, 2016, the company announced that it has completed its Phase 2 study evaluating JBT-101 ("Resunab") for the treatment of cystic fibrosis ("CF").

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information: Media Contact: info@financialbuzz.com , +1-877-601-1879

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook